Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 ...
Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s ...
After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
CDMO giant Catalent inked a deal with Sarepta Therapeutics to manufacture what looks to become the first gene therapy to treat Duchenne muscular dystrophy (DMD). In November, the FDA gave its ...
As part of its commitment to transparency, DMD published its 2024 Impact Report, detailing certified environmental performance, governance practices, and operational results aligned with SASB ...
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered acute ...
Pharmaceutical Technology on MSN
Santhera grants Agamree rights to Nxera for DMD
In October 2025, Health Canada approved Agamree from Santhera for the treatment of DMD in individuals aged four years and ...
Dr. Richard M. Sigismondi, a Long Island native and highly trained dentist with more than four decades of experience, has ...
As part of its commitment to transparency, DMD published its 2024 Impact Report, detailing certified environmental performance, governance practices, and operational results aligned with SASB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback